Evaxion's AI-Immunology platform demonstrates 86% vaccine target precision in Phase 2 personalized cancer vaccine trial ($4.39, +0.25)
Evaxion AS announces presentation of new data on its AI-Immunology platform in glioblastoma ($4.45, +0.31)
Evaxion concludes Annual General Meeting
Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01 ($3.73, 0.00)
Notice to convene Evaxion's Annual General Meeting
Evaxion AS assumed buy at Jones ($3.08, 0.00)
Transcript Intelligence: Evaxion AS Q4 Earnings Guidance
Transcript Intelligence: Evaxion AS Q4 Earnings Themes
Transcript Intelligence: Evaxion AS Q4 Earnings Q&A
Evaxion AS reports Q4 EPS ($0.02) vs year-ago ($0.21) ($3.11, 0.00)
Powered by FactSet Research Systems Inc.